-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.3%
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.3%
ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
ProMIS Neurosciences Trading Up 1.3 %
The firm has a market capitalization of $52.16 million, a PE ratio of -3.32 and a beta of 0.64. The company has a 50-day simple moving average of $5.81.
Get ProMIS Neurosciences alerts:Hedge Funds Weigh In On ProMIS Neurosciences
An institutional investor recently bought a new position in ProMIS Neurosciences stock. Ieq Capital LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,191 shares of the company's stock, valued at approximately $240,000. Ieq Capital LLC owned 0.46% of ProMIS Neurosciences at the end of the most recent quarter. Institutional investors own 0.14% of the company's stock.
ProMIS Neurosciences Company Profile
(Get Rating)ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
纳斯达克股票代码：PMN-GET Rating)上周五股价上涨1.3%，盘中一度涨至6.08美元，最新报6.08美元。午盘成交量为818股，较3,468股的平均成交量下跌76%。此前该股收盘价为6.00美元。
ProMIS Neurosciences Trading Up 1.3 %
Promis神经科学公司股价上涨1.3%
The firm has a market capitalization of $52.16 million, a PE ratio of -3.32 and a beta of 0.64. The company has a 50-day simple moving average of $5.81.
该公司市值为5,216万美元，市盈率为-3.32，贝塔系数为0.64。该公司的50日简单移动均线切入位为5.81美元。
Hedge Funds Weigh In On ProMIS Neurosciences
对冲基金参与PROMIS神经科学
An institutional investor recently bought a new position in ProMIS Neurosciences stock. Ieq Capital LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,191 shares of the company's stock, valued at approximately $240,000. Ieq Capital LLC owned 0.46% of ProMIS Neurosciences at the end of the most recent quarter. Institutional investors own 0.14% of the company's stock.
一家机构投资者最近买入了Promis神经科学股票的新头寸。根据IEQ Capital LLC最近提交给美国证券交易委员会的文件，该公司在第三季度购买了Promis NeuroScience，Inc.(纳斯达克代码：PMN-GET Rating)的新股票头寸。该机构投资者购买了39,191股该公司股票，价值约240,000美元。截至最近一个季度末，IEQ Capital LLC拥有PROMIS神经科学公司0.46%的股份。机构投资者持有该公司0.14%的股票。
ProMIS Neurosciences Company Profile
Promis神经科学公司简介
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Promis神经科学公司发现和开发用于治疗神经退行性疾病的精确医学解决方案，主要是加拿大的阿尔茨海默病(AD)、肌萎缩侧索硬化症(ALS)和多系统萎缩(MSA)。该公司的专有发现平台包括PROMIS和Collective坐标算法，用于预测错误折叠蛋白质分子表面上被称为疾病特异性表位的新靶点。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- 免费获取StockNews.com关于Promis神经科学(PMN)的研究报告
- MarketBeat：回顾一周11/14-11/18
- 目标的双重底部可能刚刚得到确认
- 美联储能涨到多高？如何进行交易
- Verra移动库存已返回空间站
- ASML的11月拉力赛有后劲吗？
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受PROMIS神经科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Promis神经科学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧